Circio Holding ASA has raised $21.1M, capital that will back the biotechnology company's work on circular RNA expression technology for gene and cell therapy.
The company's proprietary circVec platform is a modular genetic construct designed to produce multifunctional circRNA inside target cells, with applications spanning genetic medicine, cell therapy and chronic disease. Circio says the platform has shown a 75-fold increase in RNA half-life and up to 50-fold enhanced protein expression compared with conventional mRNA-based viral and non-viral vector systems. The circVec research and development work is carried out by its wholly owned subsidiary Circio AB in Stockholm, Sweden.
















